The Institute of Cancer Research has access to a range of translational funds to support the development of its research from bench to bedside.
The ICR contributes to the Faringdon Fund each year and when there is sufficient funding available we open a competition for awards. Awards of between £30,000 and £50,000 are made.
Projects are eligible for a Faringdon Fund award if there is a possibility that clear progress towards a commercialisable result will be made in the funding period with a key milestone being reached (e.g. a patent filed, effectiveness demonstrated or a prototype created).
If technically successful, the value of the project must be seen to be enhanced.
Biomedical Research Centre
The Biomedical Research Centre at The Royal Marsden NHS Foundation Trust and the ICR makes small awards to support translational research projects at the ICR and the Royal Marsden.
CRT Pioneer Fund
The CRT Pioneer Fund has been established to create a £50m+ investment fund to bridge the investment gap between cancer drug discovery and early development.
It will fund potential cancer drugs, primarily discovered by Cancer Research UK-funded scientists, from discovery through to entry to Phase II clinical trials before partnering with pharmaceutical and biotechnology companies. The CRT Pioneer Fund is managed by 6th Element Capital.